Phillips-Medisize’s manufacturing facility is located in Struer, Denmark. Credit: Phillips-Medisize - a Molex Company.
The expanded facility will include a dedicated manufacturing development and clinical build unit. Credit: Phillips-Medisize - a Molex Company.
The new facility is scheduled to be opened in the second quarter of 2020. Credit: Phillips-Medisize - a Molex Company.

Phillips-Medisize is expanding its existing global innovation and development (GID) centre in Struer, Denmark.

Announced in January 2020, the expansion involves the addition of dedicated manufacturing development and clinical build unit at the site.

The project will expand Phillips-Medisize’s clinical manufacturing capabilities, allowing the company to meet growing demand from customers in the drug delivery device market. The Struer unit is anticipated to commence operations in the second quarter of 2020.

Phillips-Medisize’s manufacturing facility expansion details

The primary objective of the facility is to support clients in late-stage development of medium and high volume products.

It will feature an agile setup for cleanroom assembly and moulding processes to serve the needs of customers, designed with 500m² of floor space to accommodate the cleanroom.

Expansion of the existing site will contribute towards expediting manufacturing and development of novel products while accelerating their availability to patients. Also, the facility will reduce launch risk for clients in the drug delivery devices domain.

Manufacturing development and clinical build unit will also boost Phillips-Medisize’s operations in Scandinavia and complement its existing activities in Copenhagen.

Details of Phillips-Medisize’s existing manufacturing facility

The existing GID centre in Struer, Denmark covers an area of 8,400m2 (90,560ft2). The facility is certified by the Canadian Medical Devices Conformity Assessment System (CMDCAS) and International Organization for Standardization (ISO) for the production of medical devices under a regulated quality management system (QMS).

Phillips-Medisize’s manufacturing facility also complies with the US Food and Drug Administration (FDA) 21 CFR Part 820 regulation and the standards of Japan’s Ministry of Health, Labour and Welfare (MHLW) and European Union’s MDD 93 / 42.

Phillips-Medisize’s product portfolio

Phillips-Medisize offers front end innovation, clinical and commercial manufacturing, as well as design and development related solutions.

The company provides integrated services to facilitate end-to-end development of products at large scale, allowing clients to bring products to market faster with lower risk. The firm also possesses electronics integration, and printed circuit board assembly (PCBA) manufacturing and assembly capabilities. It embeds electronics into drug delivery devices to improve the effectiveness of therapies.

“Manufacturing development and clinical build unit will also boost Phillips-Medisize’s operations in Scandinavia and complement its existing activities in Copenhagen.”

Phillips-Medisize leverages technology to advance the development of drug containers, providing direct use for patients, with accelerators classified into two types, drug delivery device technology accelerators and connected health technology accelerators.

Drug delivery device technology accelerators range helps in the development of injectors such as auto, pen, subcutaneous and wearable injectors. The accelerators also cover infusion devices, electronic patch pumps and cartridge and vial solutions.

Accelerators in the connected health technology category cover connected device and sensors, digital interfaces for end-users and a safe and compliant cloud database platform.

In the diagnostics market, Phillips-Medisize’s offering includes complete diagnostic devices, kits and sub-assemblies.

Marketing commentary on Phillips-Medisize

Phillips-Medisize is a subsidiary of interconnect solutions manufacturer Molex. The firm serves the pharmaceutical, medical device and diagnostics industries with solutions and services related to innovation, development and manufacturing. It primarily focuses on connected health solutions and drug delivery devices.

Headquartered in Hudson, Wisconsin, the company also provides primary pharmaceutical packaging services.

The company’s diagnostic product offerings include glucose meters, inhalation drug delivery devices, disposable insulin pen injectors, single-use surgical devices and diagnostic consumables equipment.

Phillips-Medisize has a workforce of more than 5,500 people and operates through 17 production facilities in the US, Europe, China and Mexico.

In November 2019, Phillips-Medisize opened a GID facility in Copenhagen, Denmark to support growth plans in areas such as wearable devices, injectors and connected health.

Phillips-Medisize also operates GID centres in Hudson and Fremont in the US, Struer in Denmark, Cambridge in the UK, Hillegom in the Netherlands, Suzhou in China and Bengaluru in India.